Clinical trials
Colorectal Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting colorectal cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,557 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05293470Recruiting
Tracking the real-world effects of Piqray in Korea
This study monitors how well and how safely Piqray works for people in Korea in routine care. You may be invited if your breast cancer matches specific genetic and receptor test results and you are starting Piqray for the first time.
Cheonan Si, Chungcheongnam-doAges 18–100 - NCT05295212RecruitingPhase 2
Atezolizumab plus chemo before surgery for lung cancer
This trial studies whether adding atezolizumab (an immune medicine) to standard platinum-based chemotherapy before surgery can improve outcomes for operable stage II–IIIB non-small cell lung cancer. The goal is to shrink the tumor and increase the chance the cancer can be removed with better results.
Changsha, HunanAges 18 years+ - NCT05315700RecruitingPhase 1/Phase 2
ORIC-114 for advanced lung or breast cancers with EGFR or HER2 changes
This early-phase study tests ORIC-114 to treat advanced solid tumors that have certain EGFR or HER2 genetic changes, often found in lung and breast cancers. It may help by targeting those specific cancer mutations, especially when standard treatments no longer work or aren’t tolerated.
Duarte, CaliforniaAges 18 years+ - NCT05327023RecruitingPhase 1/Phase 2
Donor immune cells after bone marrow transplant for high-risk blood cancers
This trial studies giving donor lymphocyte (immune) infusions after a bone marrow transplant for people with high-risk blood cancers. The goal is to help the immune system better fight the cancer and improve outcomes after transplant.
Bethesda, MarylandAges 12–120 - NCT05328024Recruiting
Testing who benefits from anti–PD-1 immunotherapy in head cancer
This study looks for signs in your tumor that can predict how well anti–PD-1 immunotherapy will work for certain head and neck cancers. You may benefit by helping doctors match the right treatment to the right patients.
Strasbourg, FranceAges 18 years+ - NCT05332925Recruiting
Tumor samples grown in dishes to predict immunotherapy response
This study takes small biopsy samples of your lung cancer and grows them in a dish to predict how well immunotherapy will work. If you qualify, you’ll receive standard immunotherapy (anti-PD-1/L1, with or without anti-CTLA-4), and the results from the dish-grown tumors will be compared to your real-world response.
Fairway, KansasAges 18–110 - NCT05344209RecruitingPhase 2
Pembrolizumab plus or minus vaccine for advanced lung cancer
This Phase 2 trial studies pembrolizumab (an immune-boosting cancer medicine) alone or with an added investigational UV1 vaccine in people with advanced non-small cell lung cancer. It aims to see whether adding the vaccine improves safety and effectiveness, especially in tumors with high PD-L1 levels.
Drammen, AkershusAges 18 years+ - NCT05354596Recruiting
SBRT radiation trial for central lung tumors
This trial studies a focused, high-dose radiation treatment called SBRT for lung tumors that are hard to operate on, including very central tumors near major airways or organs. It may help people control tumor growth while limiting radiation exposure to nearby critical structures.
AalborgAges 18 years+ - NCT05356182Recruiting
Low-protein meals during immunotherapy for cancer patients
This trial tests whether eating low-protein meals helps people with metastatic cancer feel better or tolerate immunotherapy (immune checkpoint inhibitors). It’s mainly a pilot/feasibility study, meaning the goal is to see if the diet is safe and doable during treatment.
Buffalo, New YorkAges 18 years+ - NCT05357651RecruitingPhase 1
LB1410 study for advanced lung, colon, and other cancers
This Phase 1 trial tests LB1410, a new cancer treatment, to see if it is safe and may work for people with advanced cancers. It focuses on specific cancer types and requires certain prior treatments and lab test results.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05371132RecruitingPhase 1
PET scan study to track immune response after SBRT
This early (Phase 1) study uses a special PET scan to measure how your immune system responds after stereotactic body radiation therapy (SBRT). The goal is to see whether the scan result can serve as a marker of immune response, which may help future treatment planning.
Duarte, CaliforniaAges 18 years+ - NCT05376592Recruiting
Study genes and weight loss in pancreatic cancer
This study looks at how a person’s genetic variations may relate to cancer-related weight loss (cachexia) in pancreatic cancer. It may help researchers better understand who is most at risk and guide future treatments.
Charlotte, North CarolinaAges 18 years+ - NCT05379803RecruitingPhase 2
High-dose furmonertinib for lung cancer with brain metastases
This trial tests a high-dose targeted pill, furmonertinib, in people with EGFR-mutated non-small cell lung cancer that has spread to the brain. It aims to better control both the lung cancer and the brain metastases by targeting a specific gene change.
Changsha, HunanAges 18 years+ - NCT05386108RecruitingPhase 1/Phase 2
Test abemaciclib plus elacestrant for breast cancer brain spread
This trial studies whether the combination of abemaciclib and elacestrant can slow or shrink ER-positive, HER2-negative breast cancer that has spread to the brain. It is designed for people whose cancer has progressed despite prior hormone (endocrine) treatment.
Fullerton, CaliforniaAges 18 years+ - NCT05423262RecruitingPhase 1/Phase 2
TRK-950 for advanced solid tumors that standard treatment can’t control
This trial tests TRK-950 in people with advanced (locally advanced or metastatic) solid tumors when standard treatments have stopped working or aren’t available. It may help by trying a new treatment approach when current options are limited.
Nagoya, Aichi-kenAges 18 years+ - NCT05431270RecruitingPhase 1/Phase 2
Test drug that targets CD73, alone or with immunotherapy
This early-stage study tests mavrostobart (an anti-CD73 antibody) to see what dose is safe and whether it can help shrink tumors. It’s studied by itself and also with a PD-1 immune therapy or chemotherapy, depending on your cancer type and prior treatments.
Huntersville, North CarolinaAges 18 years+ - NCT05431738Recruiting
Anti-migration stent for swallowing blockage from reflux cancer
This trial studies a special anti-migration stent placed in the esophagus to help keep a tumor-related blockage open and reduce reflux-related problems. It’s for adults whose swallowing is difficult because of a cancer narrowing at the esophagus-stomach junction.
ParisAges 18–91 - NCT05431595RecruitingPhase 2/Phase 3
Test a less sedating plan for agitated delirium in cancer
This study looks at whether using certain sleep/behavior medicines (called neuroleptics) with anti-seizure medicines can calm agitation from delirium without needing as much of the usual “neuroleptic” medicines. It may help people with advanced cancer who are confused and very restless or hard to settle.
Houston, TexasAges 18 years+ - NCT05436418RecruitingPhase 1/Phase 2
Lower-dose transplant medicines to prevent graft-versus-host disease
This early-phase study tests a lower dose of cyclophosphamide given after a stem cell transplant to prevent graft-versus-host disease (GVHD). It also uses sirolimus and mycophenolate to improve how well the donor immune system accepts the transplant, aiming to reduce side effects while keeping protection against GVHD.
Duarte, CaliforniaAges 12–120 - NCT05437341RecruitingPhase 1/Phase 2
CAR-T cell therapy for PSMA/CD70 tumors
This trial tests a lab-made immune cell treatment (CAR-T) designed to attack tumors that have specific markers called PSMA and/or CD70. It’s for people whose cancer has spread and can’t be fully removed with surgery, and it looks at safety and early signs of effectiveness.
Shenzhen, GuangdongAges 1–75 - NCT05438368RecruitingPhase 1/Phase 2
CAR-T therapy for tumors with GD2 or CD70 markers
This early-phase study tests a lab-made immune cell treatment (CAR-T) that targets tumor markers called GD2 and CD70. It is for people whose cancer has spread or returned and cannot be removed by surgery, to see if the treatment can work and how safe it is.
Shenzhen, GuangdongAges 1–75 - NCT05447988Recruiting
Breast reconstruction study using a new tissue expander
This trial studies a new device used during breast reconstruction after mastectomy, usually to stretch skin before placing a breast implant. It may help people who’ve had breast cancer and completed radiation at least a year ago by improving the reconstruction process and tracking outcomes.
RancaguaAges 18 years+ - NCT05450016Recruiting
Using photos and a computer to assess breast appearance after treatment
This study uses a computer (deep neural network) to judge how the breast looks after breast-conserving surgery or full breast reconstruction and radiation therapy. It may help doctors measure cosmetic results more consistently using photographs.
Mumbai, MaharashtraAges 19–80 - NCT05456256RecruitingPhase 2
LP-300 plus chemo for lung cancer in never-smokers
This Phase 2 trial tests LP-300 with carboplatin and pemetrexed to treat advanced lung adenocarcinoma in people who have never smoked. It may help shrink tumors and slow the disease in a specific genetic group of lung cancer.
Beverly Hills, CaliforniaAges 18 years+
Hear when a new Colorectal Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,557 recruiting colorectal cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced Colorectal Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- Metastatic Colorectal Cancer
- Locally Advanced Rectal Cancer
- Metastatic Colorectal Cancer (CRC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.